BR9915134A - Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição - Google Patents

Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição

Info

Publication number
BR9915134A
BR9915134A BR9915134-0A BR9915134A BR9915134A BR 9915134 A BR9915134 A BR 9915134A BR 9915134 A BR9915134 A BR 9915134A BR 9915134 A BR9915134 A BR 9915134A
Authority
BR
Brazil
Prior art keywords
therapy
treatment
individual
composition
cardiovascular disorders
Prior art date
Application number
BR9915134-0A
Other languages
English (en)
Inventor
Alfonso T Perez
Richard J Lachapelle
Barbara Roniker
Debra J Asner
John C Alexander
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of BR9915134A publication Critical patent/BR9915134A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"CO-TERAPIA E TERAPIA COMBINADA PARA O TRATAMENTO DE DISTúRBIO CARDIOVASCULAR EM UM INDIVìDUO, E, COMPOSIçãO" Combinações de um inibidor de ACE, um antagonista de aldosterona, e um diurético de alça são descritos para o uso no tratamento de distúrbios circulatórios. De interesse particular são as terapias que utilizam captopril, enalapril ou lisinopril co-administrados com espironolactona. Esta co-terapia será particularmente útil para reduzir o índice de mortalidade ou o número de hospitalizações não-fatais ou para prevenir a progressão de insuficiência cardíaca congestiva em pacientes com doença cardiovascular.
BR9915134-0A 1998-11-06 1999-11-05 Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição BR9915134A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10739898P 1998-11-06 1998-11-06
US12297799P 1999-03-05 1999-03-05
US12297899P 1999-03-05 1999-03-05
PCT/US1999/026206 WO2000027380A2 (en) 1998-11-06 1999-11-05 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease

Publications (1)

Publication Number Publication Date
BR9915134A true BR9915134A (pt) 2001-08-07

Family

ID=27380294

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915134-0A BR9915134A (pt) 1998-11-06 1999-11-05 Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição

Country Status (17)

Country Link
US (3) US6410524B1 (pt)
EP (1) EP1126880A2 (pt)
JP (1) JP2002529405A (pt)
KR (1) KR20010100986A (pt)
CN (1) CN1330556A (pt)
AU (1) AU1714000A (pt)
BR (1) BR9915134A (pt)
CA (1) CA2348885A1 (pt)
CZ (1) CZ20011590A3 (pt)
EA (1) EA003782B1 (pt)
HK (1) HK1040056A1 (pt)
HU (1) HUP0104249A3 (pt)
ID (1) ID29778A (pt)
IL (1) IL142911A0 (pt)
NO (1) NO20012229L (pt)
PL (1) PL348198A1 (pt)
WO (1) WO2000027380A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250748A1 (en) * 1999-03-05 2005-11-10 G. D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and eplerenone for treatment of cardiovascular disease
AU2001255730A1 (en) * 2000-04-26 2001-11-07 First Horizon Pharmaceutical Corporation Methods and compositions for the treatment of cardiac indications
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
DE60122898T2 (de) * 2000-07-27 2007-04-12 Pharmacia Corp. Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von kardiovaskulären krankheiten mit entzündunsbezug
WO2002009761A2 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20020111337A1 (en) * 2000-08-28 2002-08-15 Fedde Kenton N. Use of an aldosterone receptor antagonist to improve cognitive function
US7534768B2 (en) * 2000-12-13 2009-05-19 Henderson Morely Research And Development Ltd. Treatment of DNA viral infections
US20030225123A1 (en) * 2001-03-22 2003-12-04 Auerbach Bruce Jeffrey Antihypertensive agents and use
US20040156903A1 (en) * 2002-05-22 2004-08-12 Abrams Andrew L.. Metering and packaging of controlled release medication
AU2003235579A1 (en) * 2002-01-15 2003-07-30 Delta Hf. Formulations of quinapril and related ace inhibitors
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
GB0329288D0 (en) 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
EP1698058A4 (en) * 2003-12-18 2009-09-23 Inverness Medical Switzerland METHOD AND DEVICE FOR MONITORING
KR101228233B1 (ko) 2004-03-30 2013-01-31 리립사, 인크. 이온 결합 중합체 및 이의 용도
GB2413282B (en) * 2004-04-23 2009-01-14 Henderson Morley Plc DNA Viral Infections
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20060135497A1 (en) * 2004-12-17 2006-06-22 Ajay Gupta Combination therapy for treating heart disease
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20070112593A1 (en) * 2005-11-14 2007-05-17 Rxcera Pharmaceutical, Inc. Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment
US9884024B2 (en) * 2005-12-27 2018-02-06 Hemant N Joshi Physically dispersed, molecularly dissolved and/or chemically bound drug(s) in an empty, hard capsule shell composition
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
US20090076119A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched ramipril
NZ588623A (en) 2008-04-17 2012-11-30 Sanofi Aventis Use of a medicament containing dronedarone with food for preventing cardiovascular hospitalization
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
GB0819635D0 (en) * 2008-10-27 2008-12-03 Auron Invest Ltd A composition for the treatment of hypertension
US20100249081A1 (en) * 2009-03-26 2010-09-30 Ajay Gupta Compositions and methods for treatment of renal disease
US20110054033A1 (en) * 2009-08-26 2011-03-03 Virginia Tech Intellectual Properties, Inc. Methods of using abscisic acid for ameliorating hypertension and vascular inflammation
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
KR20150088243A (ko) 2012-10-08 2015-07-31 리립사, 인크. 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3257390A (en) 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
DE3506100A1 (de) 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CA2212713A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist
NZ302578A (en) 1995-02-10 2001-05-25 G A combination of a diuretic, aldosterone antagonist and an angiotensin converting enzyme inhibitor for treating cardiovascular diseases
AU4777896A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
WO1996040256A1 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone

Also Published As

Publication number Publication date
CA2348885A1 (en) 2000-05-18
US6410524B1 (en) 2002-06-25
US20040167108A1 (en) 2004-08-26
KR20010100986A (ko) 2001-11-14
IL142911A0 (en) 2002-04-21
ID29778A (id) 2001-10-11
JP2002529405A (ja) 2002-09-10
EA200100418A1 (ru) 2001-12-24
EA003782B1 (ru) 2003-08-28
AU1714000A (en) 2000-05-29
US6747020B2 (en) 2004-06-08
WO2000027380A2 (en) 2000-05-18
US20030040484A1 (en) 2003-02-27
NO20012229L (no) 2001-07-03
HUP0104249A2 (hu) 2002-04-29
WO2000027380A3 (en) 2000-08-24
NO20012229D0 (no) 2001-05-04
CN1330556A (zh) 2002-01-09
HUP0104249A3 (en) 2002-06-28
PL348198A1 (en) 2002-05-06
HK1040056A1 (zh) 2002-05-24
CZ20011590A3 (cs) 2003-01-15
EP1126880A2 (en) 2001-08-29

Similar Documents

Publication Publication Date Title
BR9915134A (pt) Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição
MY110205A (en) Imidazolyl-alkenoic acids.
BR9803168A (pt) Tratamento de parada cardìaca congestiva.
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
PE20010747A1 (es) Uso de dipiridamol o mopidamol para el tratamiento y prevencion de trastornos de la microcirculacion dependientes de fibrina
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
ID24870A (id) Penggunaan senyawa vanadium, garam dan kompleksnya yang dapat diterima secara fisiologi
BR0008781A (pt) Terapia combinada de inibidor de enzima conversora de angiotensina e antagonista de aldosterona epóxi-esteroidal para tratamento de doença cardiovascular
BR9604882A (pt) Terapia de combinação de inibidor de enzima de conversão de antgiotensina e quantidade de efeito colateral reduzido de antagonista de aldosterona para tratamento de doença cardiovascular
DE60204694D1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
DE60301862D1 (de) Kombinationsbehandlung bei akutem myokardinfarkt
BR9710038A (pt) Novas composições e matrizes radiofarmacêuticas e seus usos.
MX9707939A (es) Uso de antagonistas del factor inhibidor de la leucemia y la endotelina.
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
AR021106A1 (es) Terapia combinada de un inhibidor de la enzima convertidora de angiotensina y un antagonista de aldosterona para reducir la morbilidad y mortalidad porenfermedades cardiovasculares
WO2000061171A3 (en) Uses of mammalian ox2 protein and related reagents
WO1996024372A3 (en) Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
BR0316059A (pt) Uso de fosinopril para reduzir eventos cardiovasculares em pacientes de diálise
Ajayi et al. For the patient. New treatments for heart failure in Black people. Adjunctive sympathoplegic therapy to ACE inhibition in Blacks with congestive heart failure: a comparison of alpha-1 with beta-1 blockade on exercise tolerance and cardiac sympathovagal reflex activity
AU1067695A (en) Use of lithium compounds in the treatment of cardiac insufficiency
Neutel et al. P-373: A comparison of the effects of amlodipine 5 mg/benazepril 20 mg combination therapy to component monotherapy on arterial distensibilitly and left ventricular hypertrophy in patients with mild to moderate hypertension

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 31/401, A61K 31/341, A61P 9/00

Ipc: A61K 31/401 (2009.01), A61K 31/341 (2009.01), A61P

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8 E 13 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.